Biomarkers to predict improvement of left ventricular ejection fraction after atrial fibrillation ablation

Teodor Serban; Elisa Hennings; Ivo Strebel; Sven Knecht; Jeanne du Fay de Lavallaz; Philipp Krisai; Rebecca Arnet; Gian Völlmin; Stefan Osswald; Christian Sticherling; Michael Kühne; Patrick Badertscher

doi:10.1016/j.hrthm.2024.04.044

Biomarkers to predict improvement of left ventricular ejection fraction after atrial fibrillation ablation

Heart Rhythm. 2024 Apr 11:S1547-5271(24)02371-3. doi: 10.1016/j.hrthm.2024.04.044. Online ahead of print.

Affiliations

¹ Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
² Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland. Electronic address: patrick.badertscher@usb.ch.

PMID: 38614192
DOI: 10.1016/j.hrthm.2024.04.044

Abstract

Background: Atrial fibrillation (AF) and heart failure frequently coexist. Prediction of left ventricular ejection fraction (LVEF) recovery after catheter ablation (CA) for AF remains difficult.

Objective: The purpose of this study was to evaluate the value of biomarkers, alone and in combination with the Antwerp score, to predict LVEF recovery after CA for AF.

Methods: Patients undergoing CA for AF with depressed LVEF (<50%) were included. Plasma levels of 13 biomarkers were measured immediately before CA. Patients were categorized into "responders" and "nonresponders" in a similar fashion to the Antwerp score derivation and validation cohorts. The predictive power of the biomarkers alone and combined in outcome prediction was evaluated.

Results: A total of 208 patients with depressed LVEF were included (median age 63 years; 19% female; median indexed left atrial volume 42 mL/m²; median LVEF 43%). At a median follow-up time of 30 months, 161 (77%) were responders and 47 (23%) were nonresponders. Of 13 biomarkers, 4-angiopoietin 2 (ANG2), growth differentiation factor 15 (GDF15), fibroblast growth factor 23, and myosin binding protein C3-were significantly different between responders and nonresponders (P ≤ .001) and combined could predict the end point with an area under the curve of 0.72 (95% confidence interval [CI] 0.64-0.81) overall, 0.69 (95% CI 0.59-0.78) in heart failure with mildly reduced ejection fraction, and 0.88 (95% CI 0.77-0.98) in heart failure with reduced ejection fraction. Only ANG2 and GDF15 remained significantly associated with LVEF recovery after adjustment for age, sex, and Antwerp score and significantly improved the accuracy of the Antwerp score predictions (P < .001). The area under the curve of the Antwerp score in the outcome prediction improved from 0.75 (95% CI 0.67-0.83) to 0.78 (95% CI 0.70-0.86).

Conclusion: A biomarker panel (ANG2 and GDF15) significantly improved the accuracy of the Antwerp score.

Keywords: Angiopoietin 2; Antwerp score; Atrial fibrillation; Biomarker; Catheter ablation; Ejection fraction; Growth differentiation factor 15; Heart failure; Pulmonary vein isolation.